Benjamin J. Zeskind, who serves as the President and Chief Executive Officer of Immuneering Corp (NASDAQ:IMRX), has executed a purchase of 2,400 shares of the company's Class A Common Stock. The transaction, completed on June 23, 2026, carries a total value of $10,948. The shares were acquired at prices fluctuating between $4.55 and $4.59, resulting in a weighted average purchase price of $4.5617 per share.
Following this acquisition, Mr. Zeskind's direct ownership in Immuneering Corp stands at 2,315,252 shares. His total exposure to the company is further extended through an indirect holding managed by the Benjamin J. Zeskind 2020 Family Trust. This trust holds an additional 894,927 shares of Class A Common Stock, with his spouse, Lisa Schwartz, acting as the sole trustee.
The insider transaction occurs as Immuneering's stock trades near the $4.60 mark. The stock has demonstrated a 52% increase over the past year, although it has experienced recent weakness. According to InvestingPro analysis, IMRX appears undervalued at current levels. For deeper insights, investors can access the comprehensive Pro Research Report, available for IMRX and 1,400+ US equities.
In other recent news, Immuneering Corporation has announced the appointment of Andrew Gengos as Chief Financial Officer, effective July 16, 2026. Gengos previously served as CFO at Terns Pharmaceuticals, which was acquired by Merck & Co., Inc. for $6.7 billion.
Additionally, Immuneering has dosed its first patient in the MAPKeeper 301 trial, a phase 3 study evaluating atebimetinib in combination with modified gemcitabine/nab-paclitaxel for metastatic pancreatic cancer. This trial aims to compare the combination treatment against the standard gemcitabine/nab-paclitaxel therapy, with overall survival as the primary endpoint.
Furthermore, Mizuho has reiterated its Outperform rating for Immuneering, maintaining a $12.00 price target following updated results for atebimetinib. The updated data expanded the patient dataset to 55, revealing a median overall survival of 17.3 months. Similarly, Oppenheimer has maintained its Outperform rating with a $30.00 price target after Immuneering presented survival data at ASCO 2026. These developments reflect ongoing interest and confidence in Immuneering's drug candidate for pancreatic cancer treatment.